Nervomatrix

Company Overview

Snapshot

Founded in July 2007, Nervomatrix operates with 1–10 employees. The company has raised $3.5M across one funding round from Everett Partners. In August 2015, Nervomatrix reported successful trial results for its back pain system.

Business overview

Nervomatrix develops noninvasive, targeted neurostimulation solutions for pain relief, specifically focusing on chronic lower-back pain. Its core product, Soleve Auto-Targeted Neurostimulation, utilizes an automated robotic system with miniature probes and an electrical measurement and stimulation system to identify and target active trigger points. The company operates within the Health Tech & Life Sciences sector, serving markets such as the United States and Europe with its medical device technology.

Strategic signal

In August 2015, Nervomatrix announced successful trial results for its Soleve back pain system. This milestone is significant for investors as it provides clinical validation for the company's noninvasive neurostimulation technology, suggesting potential for market adoption and demonstrating progress in addressing chronic lower-back pain without traditional interventions like injections or steroids.

Company Intelligence Q&A

What is Nervomatrix's primary focus?

Nervomatrix focuses on developing noninvasive, targeted neurostimulation technology for chronic lower-back pain relief, utilizing its Soleve Auto-Targeted Neurostimulation system.

When was Nervomatrix founded?

Nervomatrix was founded in July 2007.

What was a key development for Nervomatrix in 2015?

In August 2015, Nervomatrix reported successful trial results for its back pain system, Soleve.

What is the total disclosed funding Nervomatrix has raised?

Nervomatrix has raised a total of $3.5M in funding, which was secured in September 2011 from Everett Partners.

Which investor participated in Nervomatrix's funding round?

In September 2011, Nervomatrix received $3.5M in funding from Everett Partners.